95 related articles for article (PubMed ID: 20631625)
21. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
[TBL] [Abstract][Full Text] [Related]
23. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
24. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
25. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.
Taylor MW; Tsukahara T; McClintick JN; Edenberg HJ; Kwo P
J Transl Med; 2008 Nov; 6():66. PubMed ID: 18986530
[TBL] [Abstract][Full Text] [Related]
26. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
28. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
[TBL] [Abstract][Full Text] [Related]
29. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
[TBL] [Abstract][Full Text] [Related]
30. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
31. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
Bárcena R; Moreno A; del Campo S; Muriel A; Mateos ML; Garrido E; García M; Quereda C; Moreno S; Moreno A
Antivir Ther; 2007; 12(3):401-6. PubMed ID: 17591030
[TBL] [Abstract][Full Text] [Related]
32. Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin.
Rodriguez-Torres M; Torriani F; Rockstroh J; Depamphilis J; Carosi G; Dieterich DT
HIV Clin Trials; 2010; 11(1):1-10. PubMed ID: 20400406
[TBL] [Abstract][Full Text] [Related]
33. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin.
Younossi ZM; Baranova A; Afendy A; Collantes R; Stepanova M; Manyam G; Bakshi A; Sigua CL; Chan JP; Iverson AA; Santini CD; Chang SY
Hepatology; 2009 Mar; 49(3):763-74. PubMed ID: 19140155
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
35. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
36. The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
François C; Coulouarn C; Descamps V; Castelain S; Brochot E; Baron A; Duchaussoy I; Capron D; Nguyen-Khac E; Duverlie G
Antimicrob Agents Chemother; 2012 Feb; 56(2):903-8. PubMed ID: 22123700
[TBL] [Abstract][Full Text] [Related]
37. Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.
Zekri AR; Bahnassy AA; Mohamed WS; Alam El-Din HM; Shousha HI; Zayed N; Eldahshan DH; Abdel-Aziz AO
Virol J; 2013 Jul; 10():218. PubMed ID: 23816271
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Martinez D; Palmer C; Simar D; Cameron BA; Nguyen N; Aggarwal V; Lloyd AR; Zekry A
Liver Int; 2015 Feb; 35(2):463-72. PubMed ID: 24461080
[TBL] [Abstract][Full Text] [Related]
39. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
Chen L; Borozan I; Feld J; Sun J; Tannis LL; Coltescu C; Heathcote J; Edwards AM; McGilvray ID
Gastroenterology; 2005 May; 128(5):1437-44. PubMed ID: 15887125
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.
Sedeño-Monge V; Santos-López G; Rocha-Gracia RC; Meléndez-Mena D; Ramírez-Mata A; Vallejo-Ruiz V; Reyes-Leyva J
Virol J; 2010 Sep; 7():243. PubMed ID: 20849643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
